FDA Questions Revlimid Dose, Toxicity And Single-Arm Study
Oncologic Drugs Advisory Committee will be asked whether Celgene’s single-arm study design is adequate to show clinical benefit in a heterogeneous disease like myelodysplastic syndromes.
Oncologic Drugs Advisory Committee will be asked whether Celgene’s single-arm study design is adequate to show clinical benefit in a heterogeneous disease like myelodysplastic syndromes.